The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

Bibliographic Details
Title: The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
Authors: José A. Carlos-Escalante, Marcela de Jesús-Sánchez, Alejandro Rivas-Castro, Pavel S. Pichardo-Rojas, Claudia Arce, Talia Wegman-Ostrosky
Source: Frontiers in Oncology, Vol 11 (2021)
Publisher Information: Frontiers Media S.A., 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: cancer, antihypertensive agents, repurposable drugs, Renin – Angiotensin – Aldosterone System, cancer therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Cancer is a complex group of diseases that constitute the second largest cause of mortality worldwide. The development of new drugs for treating this disease is a long and costly process, from the discovery of the molecule through testing in phase III clinical trials, a process during which most candidate molecules fail. The use of drugs currently employed for the management of other diseases (drug repurposing) represents an alternative for developing new medical treatments. Repurposing existing drugs is, in principle, cheaper and faster than developing new drugs. Antihypertensive drugs, primarily belonging to the pharmacological categories of angiotensin-converting enzyme inhibitors, angiotensin II receptors, direct aldosterone antagonists, β-blockers and calcium channel blockers, are commonly prescribed and have well-known safety profiles. Additionally, some of these drugs have exhibited pharmacological properties useful for the treatment of cancer, rendering them candidates for drug repurposing. In this review, we examine the preclinical and clinical evidence for utilizing antihypertensive agents in the treatment of cancer.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.660943/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2021.660943
Access URL: https://doaj.org/article/569d9d77cf0248468dfa18d1ff7e8822
Accession Number: edsdoj.569d9d77cf0248468dfa18d1ff7e8822
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2021.660943
Published in:Frontiers in Oncology
Language:English